A complete application in a minute — tailored resume and cover letter, ready to send.
Enanta Pharmaceuticals in Watertown, MA is seeking a Director/Senior Director for CMC Drug Substance Development. You will lead strategy, design scalable processes, and manage a chemist team, coordinating regulatory submissions and external partnerships.
The role requires a PhD with 10+ years in drug substance development, strong GMP experience, and cross-functional leadership to drive programs from discovery through potential commercialization. Onsite in Watertown, with some travel.
Join us in transforming the lives of patients
Are you passionate about making a significant impact in improving patients' lives? At Enanta, we are committed to discovering and developing novel small molecule drugs for indications in virology and immunology. Our collaborative, fast-paced environment empowers every team member to meaningfully contribute to our goal of advancing healthcare and improving patient outcomes.
As a Director/Senior Director, CMC Drug Substance Development, you will be an integral part of our CMC team, where your work will directly impact our innovative R&D projects. Reporting to the Vice President, CMC, you will design, execute, and lead chemical process development and manufacturing strategy to produce drug substances for GLP toxicology, clinical supplies, and potential commercialization. You will serve as a technical expert for drug substance development across the organization, lead a group of chemists, and coordinate, author, and review drug substance sections of regulatory documents. You will:
At Enanta Pharmaceuticals, you will be part of a team working on projects and programs that truly matter. We offer a supportive, inclusive environment where innovation is not just encouraged but celebrated. You’ll have the opportunity to grow, collaborate, and make a tangible impact.
Enanta is committed to providing compensation transparency. The expected base salary range for this position is $173,000 to $285,333, based on experience, qualifications, and market conditions. Offers will be determined by several factors, including individual experience and expertise, ensuring both equity and competitiveness.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
Enanta Pharmaceuticals is an equal opportunity employer (EOE) with a commitment to diversity. All individuals, regardless of personal characteristics, are encouraged to apply. All qualified applicants will receive consideration for employment without regard to race, color, national origin, age, religious creed, gender, gender identity, sexual orientation, physical or mental disability, protected veteran status, or any other class protected by law.